| Literature DB >> 24854219 |
Daniel M Hartung1, Dennis McCarty2, Rongwei Fu2, Katharina Wiest3, Mady Chalk4, David R Gastfriend5.
Abstract
Through improved adherence, once-monthly injectable extended-release naltrexone (XR-NTX) may provide an advantage over other oral agents approved for alcohol and opioid dependence treatment. The objective of this study was to evaluate cost and utilization outcomes between XR-NTX and other pharmacotherapies for treatment of alcohol and opioid dependence. Published studies were identified through comprehensive search of two electronic databases. Studies were included if they compared XR-NTX to other approved medicines and reported economic and healthcare utilization outcomes in patients with opioid or alcohol dependence. We identified five observational studies comparing 1,565 patients using XR-NTX to other therapies over 6 months. Alcohol dependent XR-NTX patients had longer medication refill persistence versus acamprosate and oral naltrexone. Healthcare utilization and costs was generally lower or as low for XR-NTX-treated patients relative to other alcohol dependence agents. Opioid dependent XR-NTX patients had lower inpatient substance abuse-related utilization versus other agents and $8170 lower total cost versus methadone.Entities:
Keywords: Alcohol dependence; Naltrexone; Opioid dependence
Mesh：
Substances：
Year: 2014 PMID： 24854219 PMCID： PMC4110954 DOI： 10.1016/j.jsat.2014.03.007
Source DB: PubMed Journal: J Subst Abuse Treat ISSN： 0740-5472